Genetically Modified NK-92 Cells and Monoclonal Antibodies for Cancer Treatment
Summary
The European Patent Office published patent application EP3273993A2 for genetically modified NK-92 cells and monoclonal antibodies used in cancer treatment. The patent is assigned to ImmunityBio, Inc. with inventors including Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel, and Kerry Campbell. The application covers designated contracting states including major European markets.
What changed
The EPO published patent application EP3273993A2 on March 25, 2026, covering genetically modified NK-92 cells and monoclonal antibodies for cancer treatment. The patent application (IPC classifications A61K 35/17, C07K 16/28, C12N 5/0783) lists ImmunityBio, Inc. as applicant and names five inventors. Designated states cover 35 European countries including all EU member states, Switzerland, Norway, and Turkey.
This is a routine patent publication notice with no compliance obligations or deadlines for third parties. Pharmaceutical companies, biotechnology firms, and healthcare providers conducting research in NK-92 cell therapy or related monoclonal antibody treatments should review this patent to assess potential freedom-to-operate implications for their own product development programs.
Source document (simplified)
GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER
Publication EP3273993A2 Kind: A2 Mar 25, 2026
Applicants
ImmunityBio, Inc.
Inventors
LEE, Tien, KLINGEMANN, Hans G., SIMON, Barry J., BOISSEL, Laurent, CAMPBELL, Kerry
IPC Classifications
A61K 40/15 20250101AFI20260122BHEP A61K 40/42 20250101ALI20260122BHEP A61K 35/17 20150101ALI20260122BHEP A61K 38/16 20060101ALI20260122BHEP A61K 39/395 20060101ALI20260122BHEP A61P 35/00 20060101ALI20260122BHEP A61P 35/02 20060101ALI20260122BHEP A61P 35/04 20060101ALI20260122BHEP A61P 43/00 20060101ALI20260122BHEP C07K 16/28 20060101ALI20260122BHEP C07K 16/32 20060101ALI20260122BHEP C12N 5/0783 20100101ALI20260122BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.